Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 2
1987 1
1990 2
1991 1
1993 1
1994 1
1995 1
1996 3
1997 2
1998 3
2000 3
2001 4
2003 4
2004 1
2005 1
2006 1
2007 4
2008 4
2009 2
2010 3
2011 2
2012 3
2013 6
2014 5
2015 1
2016 5
2017 4
2018 3
2019 3
2020 5
2021 4
2022 4
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Clear Cell Renal Cell Carcinoma"
Page 1
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. Balar AV, et al. Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26. Lancet Oncol. 2017. PMID: 28967485 Clinical Trial.
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. ...A PD-L1-expression cutoff of 10% was associated wit …
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy …
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Yan XQ, et al. Ann Oncol. 2024 Feb;35(2):190-199. doi: 10.1016/j.annonc.2023.09.3108. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37872020 Free article. Clinical Trial.
BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab pl …
BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear …
Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review.
Roy AM, Briggler A, Tippit D, Dawson K, Verma R. Roy AM, et al. Clin Genitourin Cancer. 2020 Dec;18(6):e688-e691. doi: 10.1016/j.clgc.2020.04.003. Epub 2020 Apr 21. Clin Genitourin Cancer. 2020. PMID: 32660880 Review.
Nephrectomy is the reference-standard treatment for renal-cell carcinoma (RCC). For patients with unresectable disease, tumor may be shrunk by using chemotherapy, thereby permitting surgical resection, which can be curative. ...Both tumor specimens als …
Nephrectomy is the reference-standard treatment for renal-cell carcinoma (RCC). For patients with unresectable d …
Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. Suzuki K, et al. J Immunother. 2020 Jan;43(1):38-42. doi: 10.1097/CJI.0000000000000299. J Immunother. 2020. PMID: 31567704
The objective was to elucidate the clinical features of adrenal insufficiency related to nivolumab in patients with metastatic renal cell carcinoma (mRCC). A total of 49 consecutive patients with mRCC or unresectable renal cell carcino …
The objective was to elucidate the clinical features of adrenal insufficiency related to nivolumab in patients with metastatic renal …
Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.
Krastev Z, Koltchakov V, Tomov B, Koten JW. Krastev Z, et al. Hepatogastroenterology. 2003 Jul-Aug;50(52):1006-16. Hepatogastroenterology. 2003. PMID: 12845968 Review.
Some positive results have been observed after interleukin-2 treatment, especially in melanoma, and pulmonary metastasis of renal carcinoma. ...In unresectable pancreatic head carcinoma a total response was 85% with twice prolonged survival. ...
Some positive results have been observed after interleukin-2 treatment, especially in melanoma, and pulmonary metastasis of renal …
The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.
Uemura H, Shinohara N, Tomita Y, Nonomura N, Yamada T, Yoshida A, Komoto A. Uemura H, et al. Jpn J Clin Oncol. 2023 Jul 31;53(8):730-737. doi: 10.1093/jjco/hyad034. Jpn J Clin Oncol. 2023. PMID: 37151051 Free PMC article.
METHODS: Patients with unresectable or metastatic renal cell carcinoma who started nivolumab and ipilimumab combination therapy between September 2018 and December 2019 were registered in this post-marketing surveillance. ...CONCLUSIONS: This post-mark …
METHODS: Patients with unresectable or metastatic renal cell carcinoma who started nivolumab and ipilimumab comb …
Overexpression of kif11 is a poor prognostic factor in clear cell renal cell carcinoma.
Kowalewski A, Jaworski D, Antosik P, Smolińska M, Ligmanowska J, Grzanka D, Szylberg Ł. Kowalewski A, et al. Pol J Pathol. 2022;73(2):82-87. doi: 10.5114/pjp.2022.118137. Pol J Pathol. 2022. PMID: 35979754 Free article.
INTRODUCTION: Unresectable renal cell carcinoma continues to be a great challenge due to our limited understanding of its underlying pathophysiology. We explored the relationship between KIF11 protein expression and the clinical courses of clear …
INTRODUCTION: Unresectable renal cell carcinoma continues to be a great challenge due to our limited understandi …
Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance.
Uemura H, Tomita Y, Nonomura N, Yoshizaki K, Nakao T, Shinohara N. Uemura H, et al. Int J Clin Oncol. 2022 Jun;27(6):1061-1067. doi: 10.1007/s10147-022-02155-3. Epub 2022 Apr 20. Int J Clin Oncol. 2022. PMID: 35441907 Free PMC article.
BACKGROUND: This all-case post-marketing surveillance (PMS) evaluated the real-world safety and effectiveness of nivolumab monotherapy in Japanese patients with un-resectable or metastatic renal cell carcinoma (RCC). METHODS: This multicenter, open-label, non …
BACKGROUND: This all-case post-marketing surveillance (PMS) evaluated the real-world safety and effectiveness of nivolumab monotherapy in Ja …
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME, Shah SN, Elson P, Garcia JA, Wood LS, Medsinge A, Campbell S, Dreicer R, Rini BI. Salem ME, et al. Clin Genitourin Cancer. 2014 Apr;12(2):117-23. doi: 10.1016/j.clgc.2013.08.001. Epub 2013 Oct 12. Clin Genitourin Cancer. 2014. PMID: 24126239
Neoadjuvant sunitinib might downsize unresectable renal cell carcinoma (RCC) and enable nephrectomy in a subset of patients. ...Neoadjuvant sunitinib might downsize unresectable tumors and enable nephrectomy. CT scans of unresectable prim …
Neoadjuvant sunitinib might downsize unresectable renal cell carcinoma (RCC) and enable nephrectomy in a subset …
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
BACKGROUND: Nivolumab is used after platinum-based chemotherapy in patients with metastatic urothelial carcinoma. Studies suggest improved outcomes for dual checkpoint inhibition with high ipilimumab doses. ...Adults aged 18 years or older with histologically confirmed met …
BACKGROUND: Nivolumab is used after platinum-based chemotherapy in patients with metastatic urothelial carcinoma. Studies suggest imp …
91 results